Tanzania Ministry of Health: Ketamine Reclassified as Controlled Drug

• Tanzania has reclassified ketamine and its salts as controlled drugs, effective immediately.
• The decision aims to regulate the use and distribution of ketamine, which is a powerful anesthetic and painkiller.
• Existing prescriptions and supply chains for medical professionals and patients may be impacted by the revised classification.
• Lawyers advising clients in Tanzania should be aware of the revised classification and its potential implications.

The decision to reclassify ketamine comes amid growing concerns about its misuse and diversion for non-medical purposes.

The Tanzanian government has reclassified ketamine and its salts as controlled drugs, effective immediately. This decision was made by the Ministry of Health, Community Development, Gender, Elderly, and Children in collaboration with the Tanzania Food and Drug Authority (TFDA). The move aims to regulate the use and distribution of ketamine, which is a powerful anesthetic and painkiller. According to sources, the reclassification will impact existing prescriptions and supply chains for medical professionals and patients alike.

The TFDA has been working closely with international partners to ensure that Tanzania's regulations align with global standards on controlled substances. This includes coordinating with other countries in the region to share best practices and expertise. As a result of these efforts, Tanzania is now among the first African countries to reclassify ketamine as a controlled drug.

The decision to reclassify ketamine comes amid growing concerns about its misuse and diversion for non-medical purposes. The TFDA has reported an increase in cases of ketamine abuse, particularly among young people, which has raised alarms among health officials and law enforcement agencies.

The Controlled Drugs Act of 1971 provides the legal framework for regulating controlled substances in Tanzania. The act empowers the TFDA to classify and control the use of various drugs, including ketamine. Under the revised classification, ketamine will be subject to stricter regulations, including requirements for prescription and dispensing. Medical professionals will need to obtain special licenses to prescribe or administer ketamine, while patients will require valid prescriptions from licensed healthcare providers.

The reclassification of ketamine is also expected to impact the country's supply chain management. The TFDA has announced plans to monitor and regulate the importation and distribution of ketamine, ensuring that only authorized suppliers can bring in the substance. This move aims to prevent diversion for non-medical purposes and reduce the risk of over-supply.

The decision to reclassify ketamine is part of a broader effort by the Tanzanian government to strengthen its regulatory framework on controlled substances. The country has also taken steps to regulate other substances, including khat, which is a popular stimulant in East Africa.

The reclassification of ketamine as a controlled drug has significant implications for medical professionals and patients in Tanzania. Existing prescriptions may need to be reviewed or updated, while healthcare providers will require additional training on the revised regulations. Patients who rely on ketamine for pain management or other medical conditions may face challenges accessing the substance.

Lawyers advising clients in Tanzania should be aware of the revised classification, which may impact existing supply chains and business operations. The decision to reclassify ketamine also highlights the need for closer collaboration between health officials, law enforcement agencies, and regulatory bodies to address the misuse and diversion of controlled substances.

The move is seen as a positive step towards strengthening Tanzania's regulatory framework on controlled substances, but it also raises questions about the potential impact on public health and access to essential medicines.

Lawyers advising clients in Tanzania should be aware of the revised classification, which may impact existing prescriptions and supply chains.

Source: Original reporting via Tanzanian Ministry of Health